BCR-ABL positive cells and chronic myeloid leukemia in immune suppressed organ transplant recipients

European Journal of Haematology

Volumn 84, Issue 1, 2010, Pages 26-33

  Le Coutre, Philipp ^a   Reinke, Petra ^a   Neuhaus, Ruth ^a   Trappe, Ralf ^a   Ringel, Frauke ^a   Lalancette, Marc ^b   Hemmati, Philipp G ^a   Dörken, Bernd ^a   Daniel, Peter T ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

BCR ABL; CML; Immune suppression; Solid organ transplantation

Indexed keywords

AZATHIOPRINE; BCR ABL PROTEIN; CACTINOMYCIN; CYCLOSPORIN A; CYTARABINE; DASATINIB; HYDROXYUREA; IDARUBICIN; IMATINIB; LYMPHOCYTE ANTIBODY; MESSENGER RNA; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NILOTINIB; OKT 3; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLAST CELL CRISIS; CADAVER KIDNEY; CANCER INCIDENCE; CARDIAC GRAFT REJECTION; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GRAFT RECIPIENT; HEART LUNG TRANSPLANTATION; HEART TRANSPLANTATION; HEMODIALYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKEMIA RELAPSE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; CHILD; CLONE CELLS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNOLOGIC SURVEILLANCE; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKOCYTES; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PHILADELPHIA CHROMOSOME; POSTOPERATIVE COMPLICATIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; YOUNG ADULT;

EID: 72449194808     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01357.x     Document Type: Article

References (38)

1. Silberman G, Crosse MG, Peterson EA, Weston RC, Horowitz MM, Appelbaum FR, Cheson B. Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukaemia in 10 countries. NEJM 1994 331 : 1063 1067.
2. Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell 1986 47 : 277 284.
3. Daley GQ, van Etten RA, Baltimore D. Induction of chronic myelogenous leukaemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990 247 : 824.
4. Kelliher M, Knott A, McLaughlin J, Witte ON, Rosenberg N. Differences in oncogenic potency but not target cell specificity distinguishes the two forms of the BCR/ABL oncogene. Mol Cell Biol 1991 11 : 4710.
5. Voncken JW, Kaartinen V, Pattengale PK, Germeraad WT, Groffen J, Heisterkamp N. BCR/ABL P210 and P190 cause distinct leukaemia in transgenic mice. Blood 1995 86 : 4603.
6. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006 355 : 2408 2417.
7. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998 92 : 3362 3367.
8. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995 86 : 3118 3122.
9. Nowicki MO, Falinski R, Koptyra M, Slupianek A, Stoklosa T, Gloc E, Nieborowska-Skorska M, Blasiak J, Skorski T. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004 104 : 3746 3753.
10. Shapiro R, Nalesnik M, McCauley J, Fedorek J, Jordan ML. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 1999 68 : 1851 1854.
11. Barrett WL, First MR, Aron BS, Penn I. Clinical course of malignancies in renal transplant recipients. Cance 1993 72 : 2186.
12. Ondrus D, Pribylincová V, Breza J, Bujdák P, Miklosi M, Reznícek J, Zvara V. The incidence of tumours in renal transplant recipients with long-term immunosuppressive therapy. Int Urol Nephrol 1999 31 : 417 422.
13. O'Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, McGregor JM, Walker SL, Hanaoka F, Karran P. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005 309 : 1871 1874.
14. Battin J, Hehunstre JP, Bui NB, Auzerie J, Colle M. Chronic myeloid leukaemia after immunosuppressive treatment for chronic nephropathy. Nouv Presse Med 1976 5 : 2632.
15. Adler KR, Lempert N, Scharfman WB. Chronic granulocytic leukaemia following successful renal transplantation. Cancer 1978 41 : 2206 2208.
16. Lubynski R, Disler PB, MacPhail AP, Meyers AM, Myburgh JA, Katz J. Chronic granulocytic leukaemia in a patient with a renal allograft. Arch Intern Med 1978 138 : 1429 1430.
17. Mooy JMV, Gagenouw-Taal JCW, Lameijer LDF, van Turnout JM. Chronic granulocytic leukaemia in a renal transplant recipient. Cancer 1978 41 : 7 9.
18. Hilario R, Padre-Mendoza T, Abdalla MM. Chronic granulocytic leucemia and carcinoma of the cervix in situ following renal transplantation. Am J Med Sci 1980 280 : 115 118.
19. Kirchner KA, Files JC, Didlake R, Raju S, Krueger RP. Chronic granulocytic leukaemia after renal transplantation. Arch Intern Med 1983 143 : 1984 1987.
20. Frist WH, Biggs VJ. Chronic myelogenous leukaemia after lymphoid irradiation and heart transplantation. Ann Thorac Surg 1994 57 : 214 216.
21. Sanz L, Cervantes F, Esteve J, Vilardell J, Marín P, Rozman C, Montserrat E. Chronic myeloid leukaemia after renal transplantation: report of a new case and review of the bibliography. Sangre (Barc) 1996 41 : 391 393.
22. Stein AM, Anthone R, Anthone S, Marinello MJ, Elwood CM, Bannermann RM. Chronic myelocytic leukaemia in a young renal allografted patient. Transplantation 1978 24 : 271 273.
23. Mignozzi M, Picca S. Chronic myelogenous leukaemia following kidney transplantation in a pediatric patient. Pediatr Nephrol 2001 16 : 852 853.
24. Pescovitz MD, Heerema NA, Jindal RM, Milgrom ML, Leapman SB, Filo RS. The natural history of chronic myelogenous leukaemia in a renal transplant recipient. Transplantation 1996 61 : 328 331.
25. Penn I. De novo malignancies in pediatric organ transplant recipients. Pediatr Transplant 1998 2 : 56 63.
26. Pellosos LA, Campos MG, Nascimento M, Silva MR, Pestana JO, Chauffaille Mde L. Chronic myeloid leukemia following kidney transplantation. Leuk Res 2005 29 : 353 355.
27. Koca E, Cetiner D, Goker H, Aksu S, Ozcebe OI, Haznedaroglu IC, Turgan C. Complete cytogenetic remission with imatinib mesylate treatment in chronic myelogenous leukaemia (CML) developed after renal transplantation. Clin Nephrol 2005 64 : 324 326.
28. Concejero A, Chen CL, Wang CC, Wang SH, Lin CC, Liu YW, Yang CH, Yong CC, Wang MC, Eng HL Chronic myeloid leukaemia after living donor liver transplantation. Transplantation 2007 83 : 1521 1522. (Pubitemid 46934079)
29. Thierry A, Dreyfus B, Bridoux F, Ayache RA, Milin S, Guilhot F, Touchard G. Long-term molecular efficacy of imatinib in a patient with chronic myeloid leukaemia after renal transplantation. Nephrol Dial Transplant 2007 22 : 1792.
30. Fontana V, Dudkiewicz P, Horstmann LL, Tzakis AG, Ahn YS. Atypical chronic myeloid leukaemia following organ transplants. Clin Transplant 2008 22 : 258 261.
31. Lupberger J, Kreuzer KA, Baskaynak G, Peters U, le Coutre P, Schmidt CA. Quantitative analysis of beta-actin, beta-2-microglobulin and porphobilinogen deaminase mRNA and their comparison as control transcripts for RT-PCR. Mol Cell Probes 2002 16 : 25 30.
32. Sturm I, Bosanquet AG, Hermann S, Güner D, Dörken B, Daniel PT. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 2003 10 : 477 484.
33. Deininger MW, Bose S, Gora-Tybor J, Yan XH, Goldman JM, Melo JV. Selective induction of leukemia-associated fusion genes by high-dose ionizing radiation. Cancer Res 1998 58 : 421 425.
34. Roix JJ, McQueen PG, Munson PJ, Parada LA, Misteli T. Spatial proximity of translocation-prone gene loci in human lymphomas. Nat Genet 2003 3 : 287 291.
35. Ashley T, Gaeth AP, Inagaki H, Seftel A, Cohen MM, Anderson LK, Kurahashi H, Emanuel BS. Meiotic recombination and spatial proximity in the etiology of the recurrent t(11;22). Am J Hum Genet 2006 79 : 524 538.
36. Neves H, Ramos C, Gomes da Silva M, Parreira A, Parreira L. The nuclear topography of ABL, BCR, PML, and RARα genes: evidence for gene proximity in specific phases of the cell cycle and stages of hematopoietic differentiation. Blood 1999 93 : 1197 1207.
37. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995 86 : 2041 2050.
38. Westermann J, Kopp J, van Lessen A, Hecker AC, Baskaynak G, le Coutre P, Döhner K, Döhner H, Dörken B, Pezzutto A. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia. Br J Haematol 2007 137 : 297 306.